UCB SA (OTCMKTS:UCBJF) Receives Average Rating of “Moderate Buy” from Analysts

Shares of UCB SA (OTCMKTS:UCBJF) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company.

Separately, Piper Sandler reissued a “neutral” rating on shares of UCB in a report on Wednesday.

UCB Trading Up 4.7%

Shares of UCBJF stock opened at $290.59 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company has a 50 day moving average of $292.35 and a 200-day moving average of $300.66. UCB has a 12-month low of $207.00 and a 12-month high of $345.39.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.